Beam Therapeutics Inc. Common Stock
BEAMBeam Therapeutics Inc. (BEAM) is a biotechnology company focused on developing precision genetic medicines using base editing technology. Founded to create targeted therapies for genetic diseases, Beam Therapeutics leverages its innovative editing platform to make precise, single-nucleotide modifications in DNA, aiming to treat serious medical conditions with fewer off-target effects.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| March 3, 2014 | $0.23 | 2014-02-04 | 2014-02-06 |
| December 2, 2013 | $0.23 | 2013-11-04 | 2013-11-06 |
| September 3, 2013 | $0.23 | 2013-08-12 | 2013-08-14 |
| June 3, 2013 | $0.23 | 2013-05-06 | 2013-05-08 |
| March 1, 2013 | $0.23 | 2013-02-04 | 2013-02-06 |
Dividends Summary
- Consistent Payer: Beam Therapeutics Inc. Common Stock has rewarded shareholders with 41 dividend payments over the past 10 years.
- Total Returned Value: Investors who held BEAM shares during this period received a total of $11.96 per share in dividend income.
- Latest Payout: The most recent dividend of $0.23/share was paid 4520 days ago, on March 3, 2014.
- Yield & Schedule: BEAM currently pays dividends quarterly with an annual yield of 3.29%.
- Dividend Growth: Since 2004, the dividend payout has decreased by 25.0%, from $0.30 to $0.23.
Company News
The global gene editing therapeutics market is projected to grow from USD 0.36 billion in 2026 to USD 0.65 billion by 2031, driven by CRISPR advancements, precision medicine adoption, and increased pharma investments. Key applications include oncology and rare genetic disorders, though high development costs, regulatory complexity, and safety con...
The CRISPR-based drug development platforms market is projected to grow at a CAGR of 11.4%, reaching USD 0.79 billion by 2031 from USD 0.46 billion in 2026. Growth is driven by advancements in precision medicine, gene therapy expansion, and increased biotech investments, though regulatory challenges and high development costs remain constraints.
The article compares two gene-editing biotech companies: CRISPR Therapeutics, which has an approved product (Casgevy) and a deeper pipeline, versus Beam Therapeutics, a clinical-stage company with a potentially safer base-editing platform. CRISPR Therapeutics is recommended as the better investment due to its approved product, stronger cash posit...
Beam Therapeutics presented additional clinical data from its Phase 1/2 BEAM-302 trial for alpha-1 antitrypsin deficiency (AATD) at the American Thoracic Society conference. The data from 29 patients showed durable efficacy, improved safety profile, and reduction in neutrophil elastase activity. The company plans to pursue an accelerated FDA appr...
U.S. equity markets held near record highs despite geopolitical tensions in the Middle East driving oil prices above $100/barrel. The collapse of U.S.-Iran negotiations triggered an energy shock, while major tech developments included OpenAI's partnership with Qualcomm on smartphone processors, Microsoft's loss of exclusive OpenAI access, and Chi...
